1. Pink Sheet
  2. >>Geography
  3. >>Europe

NICE Decision On Arthritis Opens Door For Biosimilars In England

UK Recommends Treating Moderate Rheumatoid Arthritis With Three Biologic Molecules

 
• By Dave Wallace

A decision by health technology assessment body NICE opens the door to broaden the use of adalimumab, etanercept and infliximab by using them to treat moderate as well as severe rheumatoid arthritis.

Pile of British money pounds sterling new one pound coins GBP in four piles close-up with NHS above. Rising cost of National Health Service concept UK
Certain biologics were found to be a cost-effective use of NHS resources for treating moderate rheumatoid arthritis

Final draft guidance published by the health technology assessment (HTA) body, NICE, has opened the door for greater use of biosimilar adalimumab, etanercept and infliximab in England by recommending that these biologic molecules be used on the National Health Service to treat moderate as well as severe rheumatoid arthritis.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

More from Europe